CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
faldaprevir +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01694706
NCT01694706Phase 1Completed

Investigation of the Effect of Food and of Increased Gastric pH on the Relative Bioavailability of a Single Oral Dose of 240 mg Faldaprevir in an Open-label, Randomised, Three-way Cross-over Trial in Healthy Subjects

Boehringer Ingelheim·interventional·Posted Sep 27, 2012·Updated Jul 30, 2015

In Brief

A Phase 1 clinical trial evaluating faldaprevir and omeprazole for Healthy. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The primary objective of this trial is to investigate the effect of food and of gastric pH increase on the relative bioavailability of faldaprevir.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 27, 2012
Enrollment StartSep 1, 2012
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.8 years ago

Interventions

faldaprevirdrug

medium dose of faldaprevir

faldaprevirdrug

medium dose of faldaprevir

omeprazoledrug

medium dose of omeprazole

faldaprevirdrug

medium dose of faldaprevir